Jubilant Pharmova

    JUBLPHARMA
    Pharma
    ₹933.60
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹14,787 Cr

    P/E
    56.38
    Day range
    ₹931.00 – ₹953.90
    52-week range
    ₹786.05 – ₹1,142.00
    Volume
    1.35 L
    Open
    ₹949.95
    Prev close
    ₹954.50

    Latest results · Q2 FY27(consolidated)Revenue ₹2,370 Cr+20.5%Profit ₹31 Cr-74.1%Margin 1.3%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 46 / 100

    Factor percentiles

    Value41
    Quality20
    Momentum49
    Low volatility74

    Derived metrics

    Earn. yield
    1.8%
    Graham no.
    ₹426.71
    vs Graham
    -54.3%
    ROE ÷ P/B
    2.8%
    12-1 mom.
    -17.6%
    Return / vol
    -0.62
    Magic Formula
    #553
    Piotroski
    1/6
    FCF yield
    -1.5%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Jubilant PharmovaJUBLPHARMA₹14,787 Cr56.382.146.0%9.0%10.0%0.60+20.5%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 11h ago

    Headlines about Jubilant Pharmova from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    51.8
    Price / Book
    2.08
    ROE (FY26)
    6.0%
    ROCE (latest year)
    9%
    Dividend yield
    0.52%

    Moving averages (NSE)

    20-day
    ₹948.55
    Price below
    50-day
    ₹978.21
    Price below
    200-day
    ₹941.98
    Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +9.6%
    Revenue YoY (Sep 2026)
    +20.5%
    Profit YoY (Sep 2026)
    -74.2%
    Operating margin
    10.0%
    Net margin
    1.3%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    -1K Cr0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%9%18%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY26-5%0%5%10%15%20%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr8K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x1x2x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date.

    FY18FY19FY20FY21FY22FY23FY24FY25FY26FY27₹0₹2.5₹5₹7.5₹10

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,6771,7591,7321,7521,8221,9291,9011,9662,1222,2902,2292,370
    Expenses1,4591,4871,4801,4631,5351,5841,6111,6251,8331,9511,9812,130
    Operating Profit218271252289287345290341289339248240
    OPM %13%15%15%17%16%18%15%17%14%15%11%10%
    Other Income49-1514108-109124-19102014
    Interest717371615653495056565458
    Depreciation951019191919598105121117127135
    Profit before tax101-54500144130206154190931768662
    Tax %34%15%4%29%23%27%34%37%40%32%35%50%
    Net Profit66-62482102101151102120561195631
    EPS in Rs₹4.19₹-3.68₹30.26₹6.45₹6.33₹9.64₹6.46₹7.55₹3.51₹7.50₹3.55₹1.96

    From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days47

    -2 days since Mar 2021

    Inventory Days170

    -98 days since Mar 2021

    Days Payable170

    +46 days since Mar 2021

    Cash Conversion Cycle47

    -147 days since Mar 2021

    Working Capital Days13

    -61 days since Mar 2021

    Strengths, risks & growth

    Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. [1]

    Strengths

    • Company has been maintaining a healthy dividend payout of 43.9%
    • Company's working capital requirements have reduced from 28.6 days to 13.4 days

    Risks

    • The company has delivered a poor sales growth of 6.31% over past five years.
    • Company has a low return on equity of 4.91% over last 3 years.
    • Company might be capitalizing the interest cost

    Compounded Sales Growth

    10 Years
    +4%
    5 Years
    +6%
    3 Years
    +10%
    TTM
    +18%

    Compounded Profit Growth

    10 Years
    +1%
    5 Years
    -13%
    3 Years
    +47%
    TTM
    -41%

    Stock Price CAGR

    10 Years
    +6%
    5 Years
    +9%
    3 Years
    +31%
    1 Year
    -17%

    Return on Equity

    10 Years
    +9%
    5 Years
    +3%
    3 Years
    +5%
    Last Year
    +7%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter47.67%47.67%47.67%47.67%0.00 pp
    FII15.96%15.90%15.87%15.37%-0.50 pp
    DII11.23%11.63%12.40%13.01%+0.61 pp
    Public24.57%24.25%23.50%23.38%-0.12 pp
    Others0.57%0.56%0.55%0.55%0.00 pp

    Filed with NSE for Sept 2026: promoters 47.68%, public 51.78%

    Analysts & fund holdings

    100%
    100% recommend buy
    2 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E56.4 vs 45.2
    Sector P/B6.05
    Beta1.02

    Who holds the shares, quarter by quarter

    Mutual funds 9.47% (+0.43 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters47.9%
    • Foreign institutions15.5%
    • Mutual funds9.5%
    • Insurance1.1%
    • Other domestic institutions2.5%
    • Retail10.7%
    • Others12.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Bandhan Small Cap Fund3.62%1.56%+0.37 pp
    Kotak Multi Cap Fund1.11%0.57%-0.03 pp
    Bandhan Focused Fund0.81%5.92%+0.56 pp
    Abakkus Flexi Cap Fund0.37%0.70%+0.69 pp
    Aditya Birla SL Small Cap Fund0.30%0.79%-0.01 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    28.8%
    Downside volatility
    27.5%
    Worst 5% of days
    2.6%
    Average of that tail
    3.8%
    Max drawdown (1Y)
    31.6%
    Below its peak
    21.0%

    Against the market

    Beta vs Nifty 50
    0.61
    Correlation
    0.28
    Relative strength (3M)
    +3.8%
    ATR (14)
    3.5%

    Return

    Return 1M
    -0.5%
    Return 3M
    +7.7%
    Return 6M
    -7.5%
    Return 1Y
    -18.0%
    vs 200-day average
    -0.9%

    Momentum

    RSI (14)
    42.7
    MACD histogram
    1.18
    Stochastic %K
    17.8
    ADX (14)
    15.6
    +DI / −DI
    13.2 / 19.8
    Money flow index
    38.6

    Participation

    Delivery (20d avg)
    44.7%
    vs its 60-day baseline
    -2.9 pts
    Volume vs 20-day
    +0.5σ
    Close vs day's VWAP
    -0.8%
    52-week position
    34 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 31 Mar 2026.

    Computed

    Piotroski F-Score

    1 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — failed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — failed
    • Asset turnover improving — failed
    Free cash flow
    -₹222 Cr
    FCF yield
    -1.5%
    Cash conversion
    3.09
    Accruals ratio
    -0.053
    Net debt
    ₹2,350 Cr
    Net debt / equity
    0.33
    EV / sales
    1.90
    Capex intensity
    17.5%
    Revenue CAGR
    18.7%
    Profit CAGR
    -21.2%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹92.8 L
    0 buys · ₹0
    1 sells · ₹92.8 L
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Jubilant Employees Welfare Trust
    ESOP
    Sell11,304₹92.8 L12 Mar 2026

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      24 Jul 2026
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      25 Jul 2025
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      2 Aug 2024
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      10 Aug 2023
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      11 Aug 2022
      ex-date
    • dividend
      ₹5.00

      Dividend - Rs 5 Per Share

      5 Aug 2021
      ex-date
    • other
      Not available — not reported in this filing

      Demerger

      4 Feb 2021
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Rs 5 Per Share

      9 Mar 2020
      ex-date
    • dividend
      ₹4.50

      Annual General Meeting/Dividend - Rs 4.50 Per Share

      12 Sept 2019
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend Rs 3 Per Share

      12 Sept 2018
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/ Dividend - Rs 3/- Per Share

      16 Aug 2017
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/ Dividend - Rs 3/- Per Share

      18 Aug 2016
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/ Dividend - Rs 3/- Per Share

      20 Aug 2015
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting / Dividend - Rs 3/- Per Share

      21 Aug 2014
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting And Dividend Rs.3/- Per Share

      14 Aug 2013
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/ Dividend Rs 3 Per Share

      14 Aug 2012
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend Rs.2/- Per Share

      10 Aug 2011
      ex-date
    • other
      Not available — not reported in this filing

      Scheme Of Demerger

      25 Nov 2010
      ex-date
    • dividend
      ₹2.00

      Annual General Meeting And Dividend Rs.2/- Per Share

      17 Sept 2010
      ex-date
    • dividend
      ₹1.50

      Dividend-Rs.1.50 Pr Share

      29 Jun 2009
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Investor Meet Outcome

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Result
    Un-Audited Financial Results For The Quarter And Half Year Ended September 30, 2026

    Un-audited Financial Results for the Quarter and Half Year ended September 30, 2026

    Board Meeting
    Board Meeting Outcome for Meeting Held On November 13, 2026

    Outcome of Board Meeting

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Company Update
    Announcement under Regulation 30 (LODR)-Allotment

    Allotment

    Company Update
    Disclosure Under Regulation 30 And Other Applicable Provisions Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Allotment Of Non-Convertible Debentures (Ncds) On A Private Placement Basis-Rs.800 Crores

    Allotment of NCD

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Earning Webinar

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026

    Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Unaudited standalone and ....

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication

    AGM/EGM
    Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    Postal Ballot Notice

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Credit Rating

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Credit Rating

    Announcement under Regulation 30 - Credit Rating

    Filed with BSE (scrip 530019); the last 45 days. Documents open at bseindia.com.

    Documents

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 14 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Jubilant Pharmova: common questions

    Answered from the figures on this page.

    Jubilant Pharmova last traded at ₹933.60 (NSE, as of 18 Nov 2026). The last session moved it down 2.19%.

    Jubilant Pharmova is valued at about ₹14,787 crore (NSE, as of 18 Nov 2026).

    Jubilant Pharmova trades at a price-to-earnings ratio of 56.38 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Jubilant Pharmova has traded between ₹786.05 and ₹1,142.00 over the past 52 weeks, to 18 Nov 2026. It is currently 41% of the way up that range.

    Jubilant Pharmova (JUBLPHARMA) is classified under Pharma on this site's screener.